DSaRM meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA's Drug Safety & Risk Management Advisory Committee will convene Feb. 10 to "receive updates on the Drug Safety Oversight Board and agency actions" on COX-2 inhibitors, an announcement in the Federal Register Jan. 6 states. The committee, which will meet from 8 am-3 pm in Gaithersburg, Md., also will be briefed on developments in the Office of Drug Safety. Since the September 2004 market withdrawal of Merck's Vioxx, FDA has hosted a three-day meeting on use of COX-2s and other NSAIDs, as well as required a black box label statement for Pfizer's Celebrex. During a meeting in May, members of the Drug Safety committee advised that FDA make its drug safety process more transparent and consider placing drug safety experts on each of its advisory committees (1"The Tan Sheet" May 30, 2005, p. 9)...
You may also be interested in...
Increased Medication Error Analysis Is Key To Improving Drug Safety – Panel
FDA should enhance its post-market monitoring of drug safety through greater surveillance of medication errors, a member of FDA's Drug Safety & Risk Management Advisory Committee said during a May 19 meeting in Silver Spring, Md
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.